Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Interim data from phase I RRx-001 study available

Jan. 29, 2013

FDA approves Gleevec for children with Ph+ ALL

Jan. 28, 2013

PD-0332991 is well tolerated in patients with recurrent or refractory advanced HCC

Jan. 28, 2013

Threshold Pharmaceuticals begins phase III MAESTRO study in pancreatic cancer

Jan. 28, 2013

Phase III trial compares linifanib and sorafenib in hepatocellular carcinoma

Jan. 28, 2013

SymBio completes phase II trial of antiemetic transdermal patch

Jan. 28, 2013

Nanjing Sanhome Pharmaceutical synthesizes new tubulin polymerization inhibitors

Jan. 28, 2013

Promising efficacy reported for veliparib in pancreatic cancer

Jan. 28, 2013

Exelixis launches Cometriq in the U.S.

Jan. 25, 2013

Results reported from phase III Japanese studies of KRN-125

Jan. 25, 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 24, 2026.
4D Nucleome opens new wave of gene regulation research, discovery
BioWorld
After a decade of research, the NIH 4D Nucleome program on July 23 delivered a wealth of new insights into how spatial changes in chromatin structure and DNA...
Other news to note for July 22, 2026
BioWorld
Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Akari, Ashlins, Azurity, Eli Lilly, Engitix, Forge Biologics,...
Brain-penetrant NLRP3 inhibitor shows promise in Parkinson’s
BioWorld Science
Researchers from Changchun Genescience Pharmaceuticals Co. Ltd. described the discovery and preclinical profile of an NLRP3 inhibitor with favorable brain...
GSK’s newly acquired Jideytro wins FDA nod in NSCLC
BioWorld
About a week after closing its $10.6 billion acquisition of Nuvalent Inc., GSK plc has reaped the first reward, announcing U.S. FDA approval of zidesamtinib in...